CNBC had the CEO of Roche on this morning and he spoke of how much more advanced companies are in their treatment of cancer. He spoke of targeting and how far they have come in attacking tumors. He was very bullish on the sector as a whole.
IMO, in order to stay ahead of the curve on oncology, I expect Roche to go after promising companies like SNTA.